Atlas Trials

An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results

Clinical trial NCT05640180 · COMPLETED

Trial details

NCT number
NCT05640180
Sponsor
Bayer
Status
COMPLETED
Study type
OBSERVATIONAL
Chronic Kidney DiseaseType 2 Diabetes
Start date
2022-11-23
Primary completion
2023-12-20
Enrollment
17847

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.